Evaluation of serum tumour markers in the lung cancer patients Source: Eur Respir J 2002; 20: Suppl. 38, 268s Year: 2002
Serum tumor markers in lung cancer patients Source: Annual Congress 2007 - Biology, diagnosis and rare tumours in thoracic malignancies Year: 2007
Role of progestrin releasing peptide (ProGRP), a serum based biomarker in early diagnosis of SCLC in cohort of high-risk patient presenting with symptoms related to lung cancer Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012
Potential diagnostic markers in bronquial fluid of patients with non small cell lung cancer (NSCLC) Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009
The prognostic value of the expression of GST-π in response to chemotherapy in cytological and pathological specimens of patients with lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 74s Year: 2002
The prognostic value of the albumin-to-fibrinogen ratio in lung cancer patients. Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019
Can high levels of serum tumor markers be useful in predicting the histologic type of lung cancer? Source: Eur Respir J 2004; 24: Suppl. 48, 77s Year: 2004
Analysis of surgical stage lung cancer and tumour markers prognostic value Source: Eur Respir J 2006; 28: Suppl. 50, 770s Year: 2006
The prognostic value of anemia, thrombocytosis and leukocytosis at time of diagnosis in patients with non-small cell lung cancer Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011
The evaluation of lung cancer patients Source: Eur Respir J 2005; 26: Suppl. 49, 323s Year: 2005
Hyaluronan: A novel sputum marker for the screening and diagnosis of lung cancer patients Source: Annual Congress 2012 - Early detection of lung cancer Year: 2012
Chemerin and PAI-1 activity as diagnostic biomarkers in resectable NSCLC:comparison to classic tumour markers Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019
The clinical value of fluorescence bronchoscopy in predicting survivals in patients with small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 150s Year: 2006
Serum angiopoietins as a clinical marker for resected early lung cancer Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology Year: 2008
Clinicopathological significance and prognostic importance of circulating plasma DNA expression in advanced non-small cell lung cancer and its efficacy as a diagnostic tool Source: Annual Congress 2012 - New insights in the pathology of lung cancer Year: 2012
The clinical value of autoflurescence bronchoscopy for precancerous lesions in operable primary lung cancer patients Source: Annual Congress 2007 - Diagnostic bronchoscopy and transthoracic aspiration Year: 2007
Screening for lung cancer Source: Eur Respir Mon; 2009: 44: 57–70 Year: 2009
Is Cyfra 21-1 serum level predictive for the type of response to treatment or survival in locally advanced and metastatic non-small cell lung cancer (NSCLC)? Source: Eur Respir J 2004; 24: Suppl. 48, 76s Year: 2004
CEA levels in the serum and induced sputum of lung cancer patients Source: Eur Respir J 2005; 26: Suppl. 49, 324s Year: 2005
Identification of genes with diagnostic and prognostic value in lung cancer. Source: International Congress 2019 – Biology of lung cancer Year: 2019